RxDoctor Payments Data

Mintie Pritchard, PA

Medical · Beckley, WVNPI 1396073656

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 420 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,616 and has fallen 61.7% since, to $618 in 2025. Among medical clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,563in general payments, 2019–2025

Across 420 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$924
  • Lilly USA, LLC$821
  • AstraZeneca$383
  • Shield Therapeutics Inc$376
  • Boehringer Ingelheim$316
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$6,551100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,563 in reported general payments places this provider in the 90th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$70,512
Medicare patients
218
Services billed
1,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$158,778
MounjaroTirzepatide111$151,084
EliquisApixaban147$135,841
JardianceEmpagliflozin82$107,855
Tresiba Flextouch U-200Insulin Degludec54$37,545
EntrestoSacubitril/Valsartan24$33,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$28,435
XareltoRivaroxaban23$25,151
LinzessLinaclotide33$24,817
FarxigaDapagliflozin Propanediol21$22,734
JanuviaSitagliptin Phosphate15$17,842
BrilintaTicagrelor20$17,533
MyrbetriqMirabegron15$15,526
JanumetSitagliptin Phos/Metformin Hcl16$14,383
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$821$164,546123 claims
Novo NordiskOzempic$924$158,77894 claims
PfizerEliquis$139$135,841147 claims
Boehringer IngelheimJardiance$316$107,85582 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Symbicort$383$57,46876 claims
NovartisEntresto$121$33,29024 claims
MerckJanuvia, Janumet$69$32,22531 claims
AbbVieLinzess, Synthroid$1,439$29,712100 claims
GSKTrelegy Ellipta$127$28,43534 claims
Johnson & JohnsonXarelto$38$25,15123 claims
Astellas Pharma US IncMyrbetriq$40$15,52615 claims
Sumitomo Pharma America, Inc.Gemtesa$33$8,13017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 233 medical providers in West Virginia.

Other medical in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →